How Oncologists Use AI to Manage Immunotherapy Toxicity

# Oncology

Doximity Ask gives oncologists a fast, reliable AI reference for grading irAEs and navigating checkpoint inhibitor toxicity, whenever they need it.

Doximity Team

Checkpoint inhibitors have changed a lot about how we treat cancer. They’ve also added a new layer of clinical complexity that most of us are still navigating: immune-related adverse events that can show up in almost any organ system, often at unpredictable times.

Grading an irAE, working through a differential on new neurologic symptoms in a patient on pembrolizumab, figuring out what to do next, these are the kinds of questions where having a fast, reliable AI reference really matters.

Oncologists are using Doximity Ask for exactly these moments, whether they’re on call, in clinic, or mid-infusion.

Example prompts

“Can you explain pembrolizumab immune-mediated neuropathy? How would it present?”

“Ddx lower extremity peripheral neuropathy in a patient with stage 4 lung cancer, now on pembrolizumab, previously on carboplatin/paclitaxel”

“CRS meaning (cytokine release syndrome secondary to immunotherapy for breast cancer)”

“Durvalumab side effects”

Try in Doximity Ask

These tend to be the on-call questions, the mid-infusion flags, the follow-up visit surprises that come with managing patients on checkpoint inhibitors.

Available when you need it

Immune-mediated toxicity doesn’t keep business hours, and neither does Doximity Ask. Because it’s designed for physicians and is HIPAA-compliant, you can include patient-specific context in your questions, the stage, the prior treatment history, the specific symptoms, and get back responses calibrated to clinical decision-making rather than general wellness guidance. That’s something a generic AI tool can’t reliably offer.

Try your next immunotherapy question at Doximity Ask .

Comments (0)

Popular